Rise in the incidence of malaria is expected to drive market expansion in the near future at a CAGR of 5.00% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published on the “Global Antimalarial Drugs Market”

Market Research Future (MRFR) has published a cooked research report on the “Global Antimalarial Drugs Market” that contains information from 2019 to 2032. The antimalarial drugs market is estimated to register a CAGR of 5.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global antimalarial drugs market - Novartis AG, Mylan N.V., Pfizer Inc., Sanofi, GlaxoSmithKline plc, Cipla Inc., Ipca Laboratories Ltd, Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries Ltd., and Others.

Antimalarial Drugs Market Highlights

The global antimalarial drugs market is accounted to register a CAGR of 5.00% during the forecast period and is estimated to reach USD 1.2 billion by 2032.

The market for antimalarial drugs is expanding due in large part to the increased incidence of malaria in emerging nations. In addition, increased government awareness campaigns and a sharp increase in research into novel antimalarial drugs are some of the other reasons driving the market's expansion. Nonetheless, a significant barrier impeding the market expansion for antimalarial drugs is the general lack of knowledge regarding healthcare in developing nations.

Segment Analysis

The global antimalarial drugs market has been segmented into drug class, malaria type, and mechanism of action.

Based on drug class, the market is segmented into Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds, and Others. The antifolate compounds segment was attributed to holding the largest market share in 2023 due to its effectiveness in combating the malaria parasite. Sulfadoxine-pyrimethamine and other antifolate medications work by preventing the synthesis of folate, which is essential for the growth and reproduction of the malaria parasite. Because of its targeted approach, which alters the parasite's life cycle, this family of drugs is useful and widely utilized for treating and preventing malaria.

Based on malaria type, the market is segmented into Plasmodium Falciparum, Plasmodium Vivax, Plasmodium Malariae, and Plasmodium Ovale. The Plasmodium Falciparum segment was attributed to holding the largest market share in 2023. In regions like Sub-Saharan Africa, where malaria transmission is widespread, the disease can have severe and often fatal effects. The development of efficient medicines to reduce the overall burden of Plasmodium falciparum is prioritized due to its clinical significance and significant contribution to malaria-related mortality.

Based on the mechanism of action, the global antimalarial drugs market has been segmented into Treatment for Malaria and Prevention from Malaria. The treatment for malaria segment was expected to hold the largest market share in 2023, spurred by the sudden demand for better treatments for malaria. With the objective of symptom relief, parasite eradication, and avoiding relapses, this stage of treatment is crucial for both straightforward and complex cases. The need for antimalarial drugs that offer quick and efficient treatment is constant due to the widespread incidence of malaria and its negative effects on public health. These drugs also help to lower the morbidity and mortality rates associated with malaria.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Antimalarial Drugs Market Insights Report

Regional Analysis

The global antimalarial drugs market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe antimalarial drugs market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The antimalarial drugs market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World antimalarial drugs market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for antimalarial drugs due to the presence of large pharmaceutical companies and high healthcare spending. Despite the low frequency of malaria in this region, exports to nations where the disease is endemic are the main drivers of the industry.

Moreover, the Europe market has been persistently growing over the forecast period because of an increase in immigration from malaria-endemic regions, an increase in tourists to those places, and the possibility of malaria reemerging in several European nations. Clinical trials and antimalarial drug development are drawn to Europe due to its strong scientific skills and healthcare facilities. As a result, it is anticipated that the need for antimalarial drugs will increase, stimulating regional market expansion and innovation, especially in regions with a higher risk of malaria.

Additionally, Asia Pacific is anticipated to experience the quickest growth over the forecast period, driven by elements like the rising incidence of malaria and the need for further research and development into treatments for the disease. Consequently, the market for antimalarial drugs is expected to develop during the forecast period. The market has also increased as a result of government and international organizations' attempts to fight malaria.

Furthermore, the rest of the world's antimalarial drugs market is divided into the Middle East, Africa, and Latin America. Due to the high rate of malaria in nations like Brazil and Peru, the market for antimalarial drugs is expanding throughout Latin America. Additionally, because of the high frequency of malaria throughout the Middle East and Africa, the region represents a significant market for antimalarial drugs.

Key Findings of the Study

• The global antimalarial drugs market is expected to reach USD 1.2 billion by 2032, at a CAGR of 5.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market owing to factors like the need for more research and development of malaria therapies as well as the disease's increased occurrence.


• Based on drug class, the antifolate compounds segment was attributed to holding the largest market in 2023.


• Novartis AG, Mylan N.V., Pfizer Inc., Sanofi, GlaxoSmithKline plc, Cipla Inc., Ipca Laboratories Ltd, Hoffmann-La Roche Ltd, and Sun Pharmaceutical Industries Ltd. are the key market players.